NuvoBio’s Post

Very insightful panel discussion moderated by Lynn Pieper Lewis of Gilmartin Group LLC with John Boyce of TigerGene LLC and Reetika B. of ARCH Venture Partners. Some main topics covered in the discussion were the need for startups executive teams s To show flexibility and willingness to pivot, the importance of an exit strategy when pitching for funding, and the difference between a “cool science” and a science with a clearly defined market, there’s a big difference. LSX USA Congress LSX - partnering for Life Science eXecutives #biotech #medtech #healthtech #scienceandtechnology #lifescience #biotechnology #drugdevelopment #marketing #networking #webdesign

According to Robert Balfour, PhD of ALSA Ventures, the abundance of choices means longer wait times for funding rounds. But what sets a company apart? 🤔 Paola Pozzi from Soffinova Partners believes it's all about the science. A strong scientific foundation can significantly boost the value of initial public offerings (IPOs). 🚀 Exciting times for #pharma! The Advanced Therapies Conference 2024 shed light on the bustling year ahead for #biotech fundraising. With a crowded landscape, investors are taking their time to sift through numerous opportunities. 💼💡 Dominic O'Regan from New Mosaic Ltd emphasizes the importance of early-stage biotechs establishing clear asset positioning and future landscape fit. 🌐 Despite a dip in private biotech venture financing in 2023, there's a glimmer of hope. GlobalData's report suggests a potential shift in investor sentiment, with 44% of healthcare professionals feeling optimistic about biotech funding recovery in the next 12 months. 📈 Let's keep an eye on this dynamic sector as it navigates through challenges and opportunities. The key to success? Standout science and strategic clarity. #biotechfunding #investment #healthcareinnovation

💼 EIS Investor Panel: Tips for Attracting Venture Capital in Retinal Innovation During the EURETINA Innovation Spotlight (EIS), venture capital experts shared valuable insights for retina specialists and researchers seeking funding for their innovative ideas. Representatives from SOFINNOVA PARTNERS, BIOGENERATION VENTURES, and MONOGRAPH BIO discussed the evolution of investment in retinal treatments over the past decade and what investors are looking for today. Here are some key takeaways: 💡 Lower-risk innovations are increasingly attractive, such as improving drug delivery and duration. 📈 Excite investors with science—investors are drawn to the full picture, from development potential to market size. 💪 Demonstrate clear advantages—ensure your innovation has an easy-to-prove, significant benefit. 🤝 Choose your partners wisely—investor relationships are partnerships, so align your goals. 🔗 Read the full article on the Euretina Congress Daily website: https://ow.ly/I5Xq50TKsVh #EURETINA24 #RetinaCare #VentureCapital #InvestmentTips #InnovationInOphthalmology #EIS2024

The question of whether or not to work with a CMO is one we have helped many of our clients answer, and it is one that has serious implications for determining a startup's success in scaling their technology. Join John Ellersick P.E. PMP tomorrow as he shares our insights from the field in this webinar collaboration with BioP2P Network! We invite all those who are interested in this topic, including current CMO facility owners and/or those who are considering becoming CMO facility owners/operators. Spread the word! Link below, thanks again to BioP2P Network for the opportunity to share. https://lnkd.in/e7Abag5R #scaleup #climatetech #CMO #bioeconomy

🎙️ In this episode of Med Tech Talks, we sit down with Dr Amir Zalcenstein, Managing Director of SYNthesis BioVentures. Amir shares his fascinating journey through venture capital and biotech, highlighting the differences between overseas and the Australian medtech landscapes, and why he loves the ASX. He also discusses SYNthesis’ unique approach to early-stage investment in Australian innovations, and says that there’s opportunities to leverage our nation’s wealth, saying: “There is a disconnect between early-stage science, early-stage financing, venture financing, and the ginormous pool of capital that is the Australian capital markets and powered by superannuation savings… you have this gigantic pool of money and you have great science. For whatever reason, there is no organic connection between them. And so what we are hoping to do is to be the ones who provide that continuity of capital.” If you're passionate about the future of med tech, biotech and venture capital, or want insights on global med tech trends, this episode is a must-listen! https://lnkd.in/gTBkj5my #MedTech #Biotech #VentureCapital #Innovation #MedTechTalks #ASX

Three experts provide valuable insights into how founders can deal with an apparent paradox: building a competent team for the demanding tasks of a biotech start-up, while at the same time financing the company is becoming increasingly difficult. Many thanks to Helena Strigård for the succinct statements. https://lnkd.in/dzXGuzBz #biotech #constares #HaegerCarlsson

Join our panel Discussion at the #SwissBiotechDay to learn more about how we build and foster pioneering partnerships

Check out this exclusive webinar. You won't want to miss it. Get ready for "Scaling Biotech: Strategies for Success," scheduled for April 23. Join us as industry experts, @BrendanMcCorkle from @SciNote and @MarkFortner from @aspenbiosciences, unveil essential strategies to successfully navigate the growth challenges in the biotech sector. This is a fantastic opportunity to gain insights from seasoned professionals about scaling your operations, leveraging technology, and staying agile in this fast-paced industry. Whether you're a startup or an established firm, these tactics are crucial for your success. Don't miss out on your chance to be part of this enlightening discussion. Secure your spot today at 👉 https://bit.ly/3VLJ3wR #BiotechGrowth #Webinar #IndustryLeaders #ScalingStrategies #Innovation #Biotechnology #BioITExpo

Life Science experts Adrian Toutoungi and Nicholas Vollers, review the key considerations from the Bruntwood SciTech event, hosted at our Cambridge office, for TechBio investors, CEOs and founders considering their exit strategy: https://bit.ly/430qo1G   Key takeaways include the importance of defining your product, an analysis of the types of exit opportunities available to TechBio companies, considerations when valuing assets and platforms, and how to approach a pharma collaboration.   #LifeSciences #TechBioExits #TechBioInvestors #PrivateWealth

🔍 What does it take to successfully scale in #HealthTech to Series B & beyond? In the HealthTech Breakfast Club February's edition the conversation delved deeper into the process of scaling beyond Series B funding, including the cohesion of leadership teams and strategic considerations regarding organic vs. inorganic growth. From looking at growth metrics to M&A target assessment when thinking about multiples, valuation and future integration both of tech and people. This month's panel was made up of: 🔹Dr. Ben Maruthappu - CEO of Cera 🔹Mong-Trang Sarrazin - CFO of Unmind 🔹Ian Coyne - Partner at Coulter Partners 🔹Michael Treskow - Partner at Eight Roads Key takeaways from the session: 🏷 Flexibility in leadership is crucial, both in response to overarching trends and when confronted with growth hurdles during the business's expansion. 📜 Domain expertise proves vital even in the early stages, enabling informed decision-making for both organic and strategic growth initiatives. This expertise also fosters credibility with investors, whether equity or debt stakeholders. 📦 Understanding unit economics is imperative for scaling operations. A meticulous focus on metrics like Customer Acquisition Cost (CAC) to Customer Lifetime Value (CLTV) for organic growth, as well as having a deep comprehension of the financial dynamics behind potential acquisitions. 🔒 M&A serve as vehicles for market expansion or product diversification. Recognizing the underlying purpose is pivotal to anticipate and address integration challenges, whether they pertain to technology infrastructure, personnel dynamics, or cultural alignment. Identifying and mitigating risks associated with execution is paramount. 🗝 Founders venturing into the healthtech sector face a distinctive risk profile. While they may exhibit a greater willingness to challenge conventional norms compared to counterparts in other industries, prioritize assembling a capable leadership team early on is key to realize their ambitious vision. Special thanks to Eight Roads for hosting this month's session at their offices and supporting this event. With Molly Gilmartin, Investment Manager AlbionVC An exciting new #TechBio chapter is coming up in March with Leigh Brody, click here to learn more: https://lnkd.in/eiPk7mGf #community #vc #founders #operators #experts #investors #venturecapital #healthcare #techbio #growth #seriesB #digitalhealth #leadershipteam #scaling